OVERVIEW

This activity's goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, this activity will address early treatment options and medical advances that can be implemented to reduce cancer-related deaths, including CAR T-cell therapy and novel therapeutics for the state-of-the-art management of newly-diagnosed and relapsed blood cancers. It will keep all healthcare professionals who care for patients with hematologic malignancies abreast of the latest scientific updates, innovative ideas, and the timeliest issues related to their care.

It will also provide participants with information to improve patient management and care strategies. They will discuss rapidly evolving developments, discover new treatments for patients, and improve practice paradigms. This activity will educate them on best practices for treating hematologic cancers and inform them of the indications to refer patients for expert quaternary-level care for advanced cellular therapies.

TARGET AUDIENCE

This activity is designed for primary care physicians, hematologists, pathologists, medical oncologists, trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to treating hematologic cancers.

LEARNING OBJECTIVES

After this activity, participants will be able to:

• Illustrate how cutting-edge data presented at the 2022 Annual Meeting of the American Society of Hematology can apply to clinical practice;
• State the emerging treatment strategies for patients with low-risk and high-risk myeloid malignancies;
• Discuss the optimal patient selection, timing, and regimen for transplant;
• Evaluate clinical trial data in the context of CAR T-cell therapy and its place in evolving hematologic malignancy treatment standards;
• Choose the optimal treatment, sequencing, and supportive care strategies for patients with lymphoma using evidence-based guidelines;
• Identify methods for integrating therapeutic advances into practice to improve current myeloma patient care;
• Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common benign hematologic diseases and COVID-associated hematologic diseases.

ACCREDITATION

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.